Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.

Autor: Sargen MR; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD., Barnhill RL; Department of Translational Research, Institut Curie, Unit of Formation and Research of Medicine University of Paris Cité, Paris, France., Elder DE; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA., Swetter SM; Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Stanford, CA., Prieto VG; Departments of Anatomic Pathology and Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ko JS; Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH., Bahrami A; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Gerami P; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL., Karunamurthy A; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA., Pappo AS; St Jude Children's Research Hospital, Memphis, TN., Schuchter LM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., LeBoit PE; Departments of Dermatology and Pathology, Helen Diller Family Cancer Center, University of California, San Francisco, San Francisco, CA., Yeh I; Departments of Dermatology and Pathology, Helen Diller Family Cancer Center, University of California, San Francisco, San Francisco, CA., Kirkwood JM; University of Pittsburgh Medical Center Hillman Cancer Center Melanoma Program, Pittsburgh, PA., Jen M; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA., Dunkel IJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Durham MM; Department of Surgery, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA., Christison-Lagay ER; Division of Pediatric Surgery, Yale School of Medicine, Yale New-Haven Children's Hospital, New Haven, CT., Austin MT; Division of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Aldrink JH; Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH., Mehrhoff C; Huntsman Cancer Institute, University of Utah Hospital, Salt Lake City, UT., Hawryluk EB; Department of Dermatology, Massachusetts General Hospital, Boston, MA.; Dermatology Program, Department of Allergy and Immunology, Boston Children's Hospital, Boston, MA., Chu EY; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Busam KJ; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Sondak V; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Messina J; Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL., Puig S; Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunye, Universitat de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain., Colebatch AJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Coughlin CC; Division of Dermatology, Departments of Medicine and Pediatrics, Washington University School of Medicine in St Louis, St Louis, MO., Berrebi KG; Departments of Dermatology and Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA., Laetsch TW; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Mitchell SG; Department of Pediatrics, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA., Seynnaeve B; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 04, pp. JCO2401154. Date of Electronic Publication: 2024 Oct 04.

Inter-rater concordance of basal cell carcinoma subtypes: influences on reporting format and opportunities for further classification modifications.

Autor: Maher NG; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Prosser N; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Aivazian K; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Colebatch AJ; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Ferguson PM; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Karim RZ; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., McKenzie CA; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Rawson RV; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Lo SN; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. Electronic address: richard.scolyer@health.nsw.gov.au.

Publikováno v: Pathology [Pathology] 2023 Oct; Vol. 55 (6), pp. 800-805. Date of Electronic Publication: 2023 Jun 07.

Biology and genetics of acquired and congenital melanocytic naevi.

Autor: Maher NG; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. Electronic address: richard.scolyer@health.nsw.gov.au., Colebatch AJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.

Publikováno v: Pathology [Pathology] 2023 Mar; Vol. 55 (2), pp. 169-177. Date of Electronic Publication: 2022 Dec 29.

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes.

Autor: Newell F; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Johansson PA; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Nones K; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Lakis V; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Pritchard AL; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; Department of Genetics and Immunology, Division of Biomedical Science, University of the Highlands and Islands, Inverness, Scotland, United Kingdom., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia., Rawson RV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Kazakoff SH; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Colebatch AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Koufariotis LT; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Ferguson PM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Wood S; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Leonard C; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Law MH; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia., Brooks KM; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Broit N; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.; Q-Gen Cell Therapeutics, Brisbane, Queensland, Australia., Palmer JM; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Couts KL; Center for Rare Melanomas, University of Colorado Cancer Center, Aurora, Colorado., Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Royal North Shore Hospital, St Leonards, New South Wales, Australia., Barbour AP; Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia., Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Shivalingam B; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Department of Neurosurgery, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.; Department of Neurosurgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Robinson WA; Center for Rare Melanomas, University of Colorado Cancer Center, Aurora, Colorado., Stretch JR; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Royal North Shore Hospital, St Leonards, New South Wales, Australia., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Mann GJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.; John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia., Pearson JV; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Waddell N; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Hayward NK; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Publikováno v: Cancer discovery [Cancer Discov] 2022 Dec 02; Vol. 12 (12), pp. 2856-2879.

Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.

Autor: Colebatch AJ; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Paver EC; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, St Leonards, NSW, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. Electronic address: richard.scolyer@health.nsw.gov.au.

Publikováno v: Pathology [Pathology] 2022 Aug; Vol. 54 (5), pp. 533-540. Date of Electronic Publication: 2022 Mar 02.